Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
The current Vertex Pharmaceuticals(VRTX) stock price is $527.00, with a market capitalization of 149.47B. The stock trades at a price-to-earnings (P/E) ratio of 27.39.
During the trading session on 2026-08-11, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $532.23 and a low of $522.01. At a current price of $527.00, the stock is +1.0% higher than the low and still -1.0% under the high.
Trading activity shows a volume of 1.07M, compared to an average daily volume of 1.5M.
The stock's 52-week range extends from a low of $362.50 to a high of $546.17.
The stock's 52-week range extends from a low of $362.50 to a high of $546.17.
VRTX News
...
BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $600.00. Unlock powerful investing too...
BofA analysts added Vertex Pharmaceuticals (VRTX) to the firm’s “US 1 List.” The list represents BofA’s best investment ideas. Unlock powerful investing tools...
Analyst ratings
78%
of 32 ratingsMore VRTX News
Image source: The Motley Fool. Monday, Aug. 3, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer and President - Dr. Reshma Kewalramani Chief Oper...
Shares of American biotech company Vertex Pharmaceuticals (VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics (SION) reported the failure o...
Technology Why Vertex Pharma Popped, As A Key Rival Plummeted 90% Licensing Vertex stock surged Monday after its competitor, Sionna Therapeutics (SION), missed...
Advertisement Earnings guidance change and new partnership set the context for Vertex Pharmaceuticals stock Vertex Pharmaceuticals (VRTX) recently reported se...
Vertex Pharmaceuticals stock has delivered a strong 155.4% return over the past 5 years, yet the current valuation picture is mixed, with the Discounted Cash Fl...
Key Points Vertex Pharmaceuticals could face competition in its most important market by far. The company is preparing for that by diversifying its lineup and...
The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reactio...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.